State-Space Compression Intrinsik Olarak Düzensiz Alfa-Synüklein için Masaüstü-Scale Hit Discovery'yi etkinleştirir

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Abstract The accessible chemical space dwarfs any tractable screening budget, and most artificial intelligence drug discovery pipelines respond by docking and ranking a small sublibrary. The resulting hit list is agnostic to selectivity, brain penetration, toxicity, synthetic accessibility, and chemical novelty. We present ISTP-DPISO DrugEngine, an end-to-end engine developed by ISTP Tech that integrates the Local Information Criticality Principle (LICP) with a Discrete Phase-Interference Search Operator (DPISO). We demonstrate the engine on the intrinsically disordered protein (IDP) α-synuclein, whose non-amyloid-component (NAC, residues 61–95) drives Parkinson-associated aggregation. The resulting LICP active set focuses the expensive LICP‑DPISO scoring: in a production‑scale run, the engine compressed a ~ 8.46×10⁸‑molecule mirror to a 10,000,000‑molecule active set (~ 85‑fold) before scoring, then converged to a compact, safety‑gated shortlist plus de novo designs. The entire campaign ran on a single desktop workstation, without any high‑performance‑computing cluster. Three engine‑prioritized, commercially available candidates (2‑D08, Uralenol, Herbacetin) and an (−)-epigallocatechin gallate (EGCG) positive control were then tested in a thioflavin‑T (ThT) aggregation assay at 100 µM: all three engine‑nominated candidates suppressed α‑synuclein aggregation, giving perfect prospective inhibitor‑call concordance (3/3 nominated); together with the EGCG positive control, all four assayed compounds inhibited aggregation (4/4 total), two by ≥ 80% plateau reduction. ISTP‑DPISO DrugEngine reframes virtual screening from post‑hoc score fusion to a single, state‑space‑compressed, safety‑gated, experimentally validated discovery pipeline.

İlgili konular